{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:12:25Z","timestamp":1772856745115,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.eururo.2005.05.015","type":"journal-article","created":{"date-parts":[[2005,6,20]],"date-time":"2005-06-20T20:04:24Z","timestamp":1119297864000},"page":"464-470","source":"Crossref","is-referenced-by-count":271,"title":["A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR Trial"],"prefix":"10.1016","volume":"48","author":[{"given":"C.R.","family":"Chapple","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Martinez-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Selvaggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Toozs-Hobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Warnack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Drogendijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bolodeoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2005.05.015_bib1","first-page":"406","article-title":"The prevelance and impact of overactive bladder in the U.S: results from the NOBLE program","volume":"20","author":"Stewart","year":"2001","journal-title":"Neurorol Urodynam"},{"issue":"9","key":"10.1016\/j.eururo.2005.05.015_bib2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"issue":"5 Suppl 2","key":"10.1016\/j.eururo.2005.05.015_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.urology.2003.09.008","article-title":"Diagnosis and treatment of the overactive bladder","volume":"62","author":"Wein","year":"2003","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.eururo.2005.05.015_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.eururo.2005.05.015_bib5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2005.05.015_bib6","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.eururo.2005.05.015_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","article-title":"Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2005.05.015_bib8","unstructured":"Gittelman M. Solifenacin succinate 10mg once daily significantly improves symptoms of overactive bladder. AUA Western Congress 2003."},{"issue":"Supplement 3","key":"10.1016\/j.eururo.2005.05.015_bib9","first-page":"94","article-title":"The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study","volume":"83","author":"Gittelman","year":"2003","journal-title":"Int J Gynaecol Obstetrics"},{"key":"10.1016\/j.eururo.2005.05.015_bib10","series-title":"Third International consultation on Incontinence","article-title":"Solifenacin associated with high persistence on therapy in long-term overactive bladder extension study","author":"Haab","year":"2004"},{"issue":"3","key":"10.1016\/j.eururo.2005.05.015_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1098-3015(10)61186-2","article-title":"Validation of the perception of bladder condition measure in overactive bladder","volume":"5","author":"Coyne","year":"2002","journal-title":"Value Health"},{"issue":"378\u2013379","key":"10.1016\/j.eururo.2005.05.015_bib12","article-title":"Mixed incontinence: how should it be treated?","volume":"21","author":"Khullar","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2005.05.015_bib13","unstructured":"Pfizer. Tolterodine Summary of Product Characteristics. 2005."},{"key":"10.1016\/j.eururo.2005.05.015_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1464-410X.2005.05294.x","article-title":"The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects","volume":"95","author":"Chapple","year":"2005","journal-title":"BJU Int"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283805003088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283805003088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T07:22:59Z","timestamp":1548400979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283805003088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0302283805003088"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2005.05.015","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}